LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

Home・Lista de Ações・MannKind Corp

MannKind Corp

Abrir

SetorSaúde

3.68 4.84

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.41

Máximo

3.63

Indicadores-chave
By Trading Economics
Rendimento	-671K -17M
Vendas	-22M 90M
P/E Médio do Setor	140.5 49.888
EPS	-0.02
Margem de lucro	-18.431
Funcionários	591
EBITDA	5.9M 3.4M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+140.41% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	180M 1B
Abertura anterior	-1.16
Fecho anterior	3.68

Sentimento de Notícias

By Acuity

67%

33%

289 / 344 Ranking em Healthcare

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jun. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 de jun. de 2026, 23:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 de jun. de 2026, 23:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 de jun. de 2026, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 de jun. de 2026, 20:51 UTC

Ganhos

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 20:09 UTC

Conversa de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 de jun. de 2026, 19:36 UTC

Conversa de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 de jun. de 2026, 19:32 UTC

Conversa de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 de jun. de 2026, 19:25 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 de jun. de 2026, 19:00 UTC

Conversa de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 de jun. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 de jun. de 2026, 18:47 UTC

Conversa de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 de jun. de 2026, 18:37 UTC

Conversa de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 de jun. de 2026, 18:27 UTC

Conversa de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 de jun. de 2026, 17:35 UTC

Conversa de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 de jun. de 2026, 17:30 UTC

Conversa de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 de jun. de 2026, 16:34 UTC

Conversa de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jun. de 2026, 15:28 UTC

Conversa de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 de jun. de 2026, 15:25 UTC

Conversa de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

140.41% parte superior

Previsão para 12 meses

Média 8.15 USD 140.41%

Máximo 11 USD

Mínimo 4.75 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

289 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.